December 9, 2021
Certara to Host Investor Day on December 15, 2021
PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an…
Pharmaceuticals, Biotechnology and Life Sciences
PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an…
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company…
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases…
Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs.…
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of…
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with…
The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®Lumbar spine BMD at 12 months vs. baseline for abalo-TDS…
BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host…
JSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune…
WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology…